Yıl: 2021 Cilt: 27 Sayı: 3 Sayfa Aralığı: 142 - 147 Metin Dili: İngilizce DOI: 10.4274/vhd.galenos.2021.2020-11-2 İndeks Tarihi: 14-06-2022

Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children

Öz:
Objectives: The aim of this study was to present real-world data regarding the efficacy and safety of tenofovir disoproxil fumarate (TDF) in pediatric patients with chronic hepatitis B (CHB). Materials and Methods: In this observational retrospective cohort study, medical records of 10 children with CHB receiving TDF were reviewed. Results: All patients were positive for hepatitis B e antigen (HBeAg) at baseline. HBV-DNA <400 copies/mL was achieved in 70% of the patients, while 20% had undetectable levels of HBV-DNA at last visit. The median HBV-DNA at baseline was approximately 8 log10 copies/mL and decrease in HBV-DNA levels after 3 months, 12 months and at last visit was approximately 3.2 log10 copies/mL, 5.2 log10 copies/mL and 6.1 log10 copies/mL, respectively. All but 1 had (n=9, 90%) elevated transaminases at baseline and serum alanine aminotransferase (ALT) levels were normalized in an average of 10.1 (3.7; 5-16) months in 7 patients. Three nucleos(t)ide-naïve patients (30%) experienced HBeAg loss and seroconversion in 12 to 18 months. There were no observed serious adverse events. Renal function was maintained well through follow-up in all patients. Conclusion: Tenofovir monotherapy is effective in terms of virologic and biochemical responses in pediatric patients with CHB. Tenofovir has a favorable safety profile.
Anahtar Kelime:

Çocuklarda Kronik Hepatit B Enfeksiyonunda Tenofovir Disoproksil Fumarat Tedavisi

Öz:
Amaç: Bu çalışmanın amacı, pediatrik kronik hepatit B (KHB) tedavisinde tenofovir disoproksil fumaratın (TDF) etkinliği ve güvenliği ile ilgili verileri sunmaktır. Gereç ve Yöntemler: Bu gözlemsel retrospektif kohort çalışmasında, TDF tedavisi alan KHB enfeksiyonu olan 10 çocuğun tıbbi kayıtları geriye dönük olarak incelendi. Bulgular: Tedavi başlangıcında tüm hastalarda hepatit B e antijen (HBeAg) pozitifti. Son poliklinik kontrolünde, hastaların %70’inde HBV-DNA <400 kopya/mL olarak saptanırken, %20’sinde HBV-DNA negatifti. Başlangıçtaki ortanca HBV-DNA değeri yaklaşık 8 log10 kopya/mL idi ve 3. ay, 12. ay ve son kontrolde HBV-DNA değerlerinde sırasıyla yaklaşık 3,2 log10 kopya/mL, 5,2 log10 kopya/mL ve 6,1 log10 kopya/mL düşüş saptandı. Tedavi başlangıcında biri hariç tüm hastaların (n=9, %90) serum alanin aminotransferaz (ALT) seviyeleri yüksekti ve 7 hastada ortalama 10,1 (3,7; 5-16) ayda ALT seviyesi normale döndü. Daha önce hiç nükleoz(t)it analoğu almayan 3 hastada (%30), 12 ila 18 ayda HBeAg kayboldu ve serokonversiyon görüldü. Hastaların hiçbirinde ciddi yan etki gözlemlenmedi. Hastaların takipleri boyunca böbrek fonksiyonları normal sınırlarda seyretti. Sonuç: Tenofovir monoterapisi, KHB enfeksiyonu olan pediatrik hastalarda virolojik ve biyokimyasal tedavi hedeflerine ulaşmak açısından etkilidir. Çocuklarda tenofovir tedavisi güvenlidir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219.
  • 2. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. [World Health Organisation web site]. March 2015. : Available at: http://www.who.int/hiv/pub/hepatitis/ hepatitis-b-guidelines/en/
  • 3. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995;22:1387-1392.
  • 4. Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med. 2017;5:37.
  • 5. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012;56:2018-2026.
  • 6. Evaluating the efficacy, safety and tolerability of tenofovir df in pediatric patients with chronic hepatitis B infection. ClinicalTrials. gov Identifier: NCT01651403 [U.S. National Library of Medicine ClinicalTrials.gov web site]. July 27, 2012. : Available at: https:// clinicaltrials.gov/ct2/show/NCT01651403
  • 7. Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR. Antiviral efficacy of tenofovir monotherapy in children with nucleos(t)idenaive chronic hepatitis B. J Korean Med Sci. 2018;33:e11.
  • 8. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-Vergani G; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol. 2013;59:814- 829.
  • 9. Wang HL, Lu X, Yang X, Xu N. Antiviral therapy in lamivudine-resistant chronic hepatitis b patients: a systematic review and network metaanalysis. Gastroenterol Res Pract. 2016;2016:3435965.
  • 10. Kocak N, Ozen H, Saltik IN, Gürakan F, Yüce A. Lamivudine for children with chronic hepatitis B. Am J Gastroenterol. 2000;95:2989- 2990.
  • 11. Kocak N, Saltik IN, Ozen H, Yüce, Gürakan F. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology. 2000;31:545.
  • 12. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346:1706- 1713.
  • 13. European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
  • 14. Goyal SK, Dixit VK, Shukla SK, Ghosh J, Behera M, Tripathi M, Gupta N, Ranjan A, Jain AK. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Indian J Gastroenterol. 2015;34:286-291.
  • 15. Alsohaibani F, Alturaif N, Abdulshakour A, Alghamdi S, Alshaibani A, Alashgar H, Alkahtani K, Kagevi I. Tenofovir in the treatment of naive and refractory chronic Hepatitis B: A single center experience in Saudi Arabia. Saudi J Gastroenterol. 2015;21:295-299.
  • 16. Jung SK, Kim KA, Ha SY, Lee HK, Kim YD, Lee BH, Paik WH, Kim JW, Bae WK, Kim NH, Lee JS, Jwa YJ. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients. Clin Mol Hepatol. 2015;21:41-48.
  • 17. Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol. 2015;21:2746-2753.
  • 18. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73- 80.
  • 19. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, Lok AS. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854-1863.
  • 20. Jonas MM, Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Mouchli MA, Singh S, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology. 2016;63:307-318.
  • 21. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, Menson E, Butler K, Gibb D, Collaborative H. I. V. Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204-209.
  • 22. Judd A, Boyd KL, Stohr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525-534.
  • 23. Purswani M, Patel K, Kopp JB, Seage GR, 3rd, Chernoff MC, Hazra R, Siberry GK, Mofenson LM, Scott GB, Van Dyke RB, Pediatric Hivaids Cohort Study. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495-500.
  • 24. Viganò A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, Penagini F, Caprio C, Zuccotti GV.. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011;31:407-415.
  • 25. Della Negra M, de Carvalho AP, de Aquino MZ, da Silva MT, Pinto J, White K, Arterburn S, Liu YP, Enejosa JV, Cheng AK, Chuck SL, Rhee MS. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31:469-473.
APA gumus e, Karhan A, hizarcioglu gulsen h, demir h, saltik temizel i (2021). Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. , 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
Chicago gumus ersin,Karhan Asuman Nur,hizarcioglu gulsen hayriye,demir hulya,saltik temizel inci nur Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. (2021): 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
MLA gumus ersin,Karhan Asuman Nur,hizarcioglu gulsen hayriye,demir hulya,saltik temizel inci nur Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. , 2021, ss.142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
AMA gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. . 2021; 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
Vancouver gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. . 2021; 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
IEEE gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i "Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children." , ss.142 - 147, 2021. 10.4274/vhd.galenos.2021.2020-11-2
ISNAD gumus, ersin vd. "Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children". (2021), 142-147. https://doi.org/10.4274/vhd.galenos.2021.2020-11-2
APA gumus e, Karhan A, hizarcioglu gulsen h, demir h, saltik temizel i (2021). Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal, 27(3), 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
Chicago gumus ersin,Karhan Asuman Nur,hizarcioglu gulsen hayriye,demir hulya,saltik temizel inci nur Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal 27, no.3 (2021): 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
MLA gumus ersin,Karhan Asuman Nur,hizarcioglu gulsen hayriye,demir hulya,saltik temizel inci nur Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal, vol.27, no.3, 2021, ss.142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
AMA gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal. 2021; 27(3): 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
Vancouver gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children. Viral Hepatitis Journal. 2021; 27(3): 142 - 147. 10.4274/vhd.galenos.2021.2020-11-2
IEEE gumus e,Karhan A,hizarcioglu gulsen h,demir h,saltik temizel i "Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children." Viral Hepatitis Journal, 27, ss.142 - 147, 2021. 10.4274/vhd.galenos.2021.2020-11-2
ISNAD gumus, ersin vd. "Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children". Viral Hepatitis Journal 27/3 (2021), 142-147. https://doi.org/10.4274/vhd.galenos.2021.2020-11-2